Compare · ABT vs CSCI
ABT vs CSCI
Side-by-side comparison of Abbott Laboratories (ABT) and COSCIENS Biopharma Inc. (CSCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CSCI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $155.82B.
- ABT has hit the wire 27 times in the past 4 weeks while CSCI has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for CSCI).
- Company
- Abbott Laboratories
- COSCIENS Biopharma Inc.
- Price
- -
- -
- Market cap
- $155.82B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 27
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
- Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)
- Director Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)
- Director O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)
- Director Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)
Latest CSCI
- COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
- COSCIENS Biopharma Inc. Announces Leadership Change
- COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- SEC Form 25 filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
- COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
- SEC Form 6-K filed by COSCIENS Biopharma Inc.
- SEC Form 6-K filed by COSCIENS Biopharma Inc.